Wow!..92 % reduction..
Who said Antisense Gen2 was useless...
ISIS-TTRRx is a gen 2.0+ antisense drug Isis is developing with GSK for the treatment of TTR amyloidosis. ISIS-TTRRx is administered as a once weekly subcutaneous injection and is designed to inhibit the production of all forms of TTR protein, including both mutant and wild type, offering a unique approach to treat all types of TTR amyloidosis.
Read more: http://www.nasdaq.com/press-release...-ttr-amyloidosis-20150422-01191#ixzz3Y7xnLI2R
ANP a Company in the making., page-20
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
13.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $117.2M | |||
| Open | High | Low | Value | Volume |
| 13.5¢ | 14.0¢ | 13.0¢ | $168.5K | 1.260M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 633259 | 13.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.5¢ | 874939 | 7 |
View Market Depth
| Last trade - 16.10pm 14/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |